Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR plus ) metastatic breast cancer (MBC).

被引：0
|
作者：
Tan, Antoinette R.
Wong, Serena Tsan-Lai
Warren, Robert D.
Eng-Wong, Jennifer
Liu, Minetta C.
Zelnak, Amelia Bruce
Lin, Yong
Shih, Weichung
Ganesan, Shridar
Grana, Generosa
Isaacs, Claudine
Toppmeyer, Deborah
机构：
[1] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[2] Lombardi Canc Ctr, Washington, DC USA
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] Mayo Clin, Rochester, MN USA
[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[6] Cooper Univ Hosp, Camden, NJ USA
[7] Lombardi Comprehens Canc Ctr, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.531
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
531
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Q-TWiST analysis of lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive (HR plus ) metastatic breast cancer (MBC)
    Sherrill, B.
    Amonkar, M.
    Sherif, B.
    Maltzman, J.
    O'Rourke, L.
    Johnston, S.
    EJC SUPPLEMENTS, 2009, 7 (02): : 275 - 275
  • [2] Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer
    Schwarzberg, Lee S.
    Franco, Sandra X.
    Florance, Allison
    O'Rourke, Lisa
    Maltzman, Julie
    Johnston, Stephen
    ONCOLOGIST, 2010, 15 (02): : 122 - 129
  • [3] An open-label study of sunitinib (SU) plus exemestane (E) in the first-line treatment of hormone receptor (HR)-positive metastatic breast cancer (MBC)
    Ahlgren, P.
    Thirlwell, M.
    O'Regan, R.
    Mormont, C.
    Levesque, L.
    Gaspo, R.
    Woloj, M.
    Bello, A.
    Martell, B.
    Leyland-Jones, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive HER2+metastatic breast cancer (MBC): A quality-of-life (QOL) analysis
    Sherif, B. N.
    Sherrill, B.
    Amonkar, M.
    Wu, Y.
    Maltzman, J.
    O'Rourke, L.
    Johnston, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.
    Basaran, Gul
    Demirci, Umut
    Yildiz, Fatih
    Cicin, Irfan
    Aktas, Burak Yasin
    Ozturk, Banu
    Goksu, Sema Sezgin
    Coskun, Hasan Senol
    Oyan, Basak
    Sonmez, Ozlem
    Eralp, Yesim
    Gokmen, Erhan
    Gunduz, Seyda
    Korkmaz, Taner
    Sendur, Mehmet Ali Nahit
    Keskin, Serkan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
    Johnston, Stephen
    Pippen, John, Jr.
    Pivot, Xavier
    Lichinitser, Mikhail
    Sadeghi, Saeed
    Dieras, Veronique
    Gomez, Henry Leonidas
    Romieu, Gilles
    Manikhas, Alexey
    Kennedy, M. John
    Press, Michael F.
    Maltzman, Julie
    Florance, Allison
    O'Rourke, Lisa
    Oliva, Cristina
    Stein, Steven
    Pegram, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5538 - 5546
  • [7] A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
    Barroso-Sousa, Romualdo
    Krop, Ian E.
    Trippa, Lorenzo
    Tan-Wasielewski, Zhenying
    Li, Tianyu
    Osmani, Wafa
    Andrews, Chelsea
    Dillon, Deborah
    Richardson, Edward T.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Schoenfeld, Jonathan Daniel
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Safety of First-Line Letrozole Compared with Lapatinib Plus Letrozole in Patients with Postmenopausal Hormone Receptor Positive Metastatic Breast Cancer: EGF30008 Study
    Ro, J.
    Pippen, J.
    Pivot, X.
    Manikhas, A.
    Fehrenbacher, L.
    Makris, A.
    Florance, A.
    Maltzman, J.
    O'Rourke, L.
    Johnson, S.
    CANCER RESEARCH, 2009, 69 (24) : 796S - 797S
  • [9] A phase II parallel group study with letrozole plus goserelin in premenopausal, and letrozole in postmenopausal metastatic breast cancer patients as first line hormone therapy
    Ro, J.
    Lee, K. S.
    Han, H.
    Lee, E.
    Kang, H. S.
    Kim, S. W.
    Kwon, Y.
    Nam, B.
    EJC SUPPLEMENTS, 2008, 6 (07): : 176 - 176
  • [10] Exploratory biomarkers in MONARCH 1, a phase II study of abemaciclib monotherapy in hormone-receptor positive (HR) HER2-metastatic breast cancer (MBC)
    Tolaney, S. M.
    Cortes, J.
    Dickler, M. N.
    Zamora, E.
    Caldwell, C. W.
    Nguyen, T. S.
    Nanda, S.
    Koustenis, A.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2016, 27
12345